Question 1
What guidelines or protocols do you refer to regarding the management of patients with:
a) Systemic lupus erythematosus (SLE)
b) Lupus nephritis (LN)
Question 2
Please detail the number of patients that were admitted as an inpatient or day case in the last 12 months for the following primary diagnosis: (M321)
Question 3
Do you refer patients within the ICD10 code M321 to another Trust?
3a. If you answered ‘Yes’, please detail which Trusts you refer patients to.
Question 4
Is there a specific clinic for LN patients at your Trust?
Question 5
Please complete the number of patients prescribed with the following products in the last 12 months within the ICD10 code Systemic lupus erythematosus with organ or system involvement (M321):
i. Azathioprine
ii. Belimumab
iii. Ciclosporin
iv. Cyclophosphamide
v. Mycophenolate mofetil
vi. Oral tacrolimus
Question 6
Has a shared care agreement/arrangement been established between your institution and primary care for the treatment of lupus nephritis?
6a. If you answered ‘Yes’, which of the following medicines can be prescribed within the shared care agreement?
i. Azathioprine
ii. Ciclosporin
iii. Cyclophosphamide
iv. Mycophenolate mofetil (MMF)
v. Oral tacrolimus
Question 7
Has a shared care agreement/arrangement been established between your institution and a tertiary centre for the treatment of lupus nephritis?
7a. If so, please specify what medicines can be prescribed in secondary care within these shared care agreements.
Question 8
What is the name of your local integrated care system?
Question 9
For the LN patient pathway, is care commissioned by:
Activity Block contract
Blended payment

Download response Systemic lupus erythematosus (SLE) and Lupus nephritis (LN). 251121.docx